World antibody-drug conjugate summit, october 15-16, 2013, San Francisco, CA

mAbs

Volumn 6, Issue 1, 2014, Pages 18-29

  Klinguer Hamour, Christine ^a   Strop, Pavel ^b   Shah, Dhaval K ^c   Ducry, Laurent ^d   Xu, April ^b   Beck, Alain ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b PFIZER INC   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d LONZA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; ANTIGEN; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LAPATINIB; LEUPRORELIN; LYSINE; PACLITAXEL; PERTUZUMAB; PREDNISOLONE; TAXANE DERIVATIVE; TEMOZOLOMIDE; TOXIC SUBSTANCE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; BIOTECHNOLOGY; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DRUG CONJUGATION; DRUG INDUSTRY; DRUG MANUFACTURE; GLYCOSYLATION; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROCESS DEVELOPMENT; PROSTATE CANCER; SOLID TUMOR; UNITED STATES;

ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CONGRESSES AS TOPIC; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; NEOPLASMS;

EID: 84892580514     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.27437     Document Type: Article

References (24)

1. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/ nri2747
2. Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaïa N. The next generation of antibody-drug conjugates comes of age. Discov Med 2010; 10:329-39; PMID:21034674
3. Beck A, Senter P, Chari R. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. MAbs 2011; 3:331-7; PMID:21691144; http://dx.doi.org/10.4161/ mabs.3.4.16612
4. Beck A, Lambert J, Sun M, Lin K. Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. MAbs 2012; 4:637-47; PMID:22909934; http://dx.doi. org/10.4161/mabs.21697
5. Strop P, Liu SH, Dorywalska M, Delaria K, Dushin RG, Tran TT, Ho WH, Farias S, Casas MG, Abdiche Y, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 2013; 20:161-7; PMID:23438745; http://dx.doi.org/10.1016/j. chembiol.2013.01.010
6. Jeger S, Zimmermann K, Blanc A, Grünberg J, Honer M, Hunziker P, Struthers H, Schibli R. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew Chem Int Ed Engl 2010; 49:9995-7; PMID:21110357; http://dx.doi. org/10.1002/anie.201004243
7. Ogasawara AF, Vanderbilt J, Tinianow A, Gill J, Kan H. Tumor uptake and efficacy of antibody drug conjugates using 89Zirconium immunoPET. P822. 2011 World Molecular Imaging Congress, San Diego, California.
8. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23:4591-601; PMID:15837970; http://dx.doi. org/10.1200/JCO.2005.05.160 (Pubitemid 46224061)
9. Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn 2012; 39:643-59; PMID:23151991; http://dx.doi.org/10.1007/s10928-012-9276-y
10. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 2012; 39:67-86; PMID:22143261; http://dx.doi.org/10.1007/ s10928-011-9232-2
11. Chudasama VL, Schaedeli Stark F, Harrold JM, Tibbitts J, Girish SR, Gupta M, Frey N, Mager DE. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther 2012; 92:520-7; PMID:22968044; http://dx.doi. org/10.1038/clpt.2012.153
12. Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, Krop IE, Girish S, Friberg LE, Gupta M. A population pharmacokinetic/ pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 2012; 70:591-601; PMID:22886072; http://dx.doi.org/10.1007/s00280-012-1934-7
13. Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, Barton HA, Betts AM. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. J Pharmacokinet Pharmacodyn 2013; 40:557-71; PMID:23933716; http://dx.doi. org/10.1007/s10928-013-9329-x
14. Shah DK, Barletta F, Betts A, Hansel S. Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers' perspective. Bioanalysis 2013; 5:989-92; PMID:23641690; http://dx.doi.org/10.4155/bio.13.78
15. Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, de Sauvage FJ, Eaton D, Elkins K, Elliott JM, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009; 69:2358-64; PMID:19258515; http://dx.doi. org/10.1158/0008- 5472.CAN-08-2250
16. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008; 26:925-32; PMID:18641636; http://dx.doi.org/10.1038/nbt.1480
17. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003; 21:211-22; PMID:12525512; http://dx.doi.org/10.1200/ JCO.2003.05.137 (Pubitemid 46606149)
18. Beck A. Review of Antibody-Drug Conjugates, Methods in Molecular Biology series: A book edited by Laurent Ducry. MAbs. 2013; 6: in press.
19. Carrico IS, Carlson BL, Bertozzi CR. Introducing genetically encoded aldehydes into proteins. Nat Chem Biol 2007; 3:321-2; PMID:17450134; http:// dx.doi.org/10.1038/nchembio878 (Pubitemid 46789266)
20. Wu P, Shui W, Carlson BL, Hu N, Rabuka D, Lee J, Bertozzi CR. Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag. Proc Natl Acad Sci U S A 2009; 106:3000-5; PMID:19202059; http://dx.doi.org/10.1073/ pnas.0807820106
21. Rabuka D. Chemoenzymatic methods for sitespecific protein modification. Curr Opin Chem Biol 2010; 14:790-6; PMID:21030291; http://dx.doi. org/10.1016/j.cbpa.2010.09.020
22. Hudak JE, Barfield RM, de Hart GW, Grob P, Nogales E, Bertozzi CR, Rabuka D. Synthesis of heterobifunctional protein fusions using copper-free click chemistry and the aldehyde tag. Angew Chem Int Ed Engl 2012; 51:4161-5; PMID:22407566; http://dx.doi.org/10.1002/anie.201108130
23. Rabuka D, Rush JS, deHart GW, Wu P, Bertozzi CR. Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat Protoc 2012; 7:1052-67; PMID:22576105; http://dx.doi. org/10.1038/nprot.2012.045
24. Agarwal P, Kudirka R, Albers AE, Barfield RM, de Hart GW, Drake PM, Jones LC, Rabuka D. Hydrazino-pictet-spengler ligation as a biocompatible method for the generation of stable protein conjugates. Bioconjug Chem 2013; 24:846-51; PMID:23731037; http://dx.doi.org/10.1021/bc400042a